ME03567B - Biotin za lečenje demijelinizacionih neuropatija - Google Patents

Biotin za lečenje demijelinizacionih neuropatija

Info

Publication number
ME03567B
ME03567B MEP-2019-285A MEP2019285A ME03567B ME 03567 B ME03567 B ME 03567B ME P2019285 A MEP2019285 A ME P2019285A ME 03567 B ME03567 B ME 03567B
Authority
ME
Montenegro
Prior art keywords
biotin
demyelinating neuropathies
treating demyelinating
treating
neuropathies
Prior art date
Application number
MEP-2019-285A
Other languages
German (de)
English (en)
French (fr)
Inventor
Frédéric Sedel
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03567(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of ME03567B publication Critical patent/ME03567B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Magnetic Ceramics (AREA)
  • Manufacture, Treatment Of Glass Fibers (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MEP-2019-285A 2015-03-26 2016-03-25 Biotin za lečenje demijelinizacionih neuropatija ME03567B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305437.4A EP3072513A1 (en) 2015-03-26 2015-03-26 Biotin for treating Amyotrophic lateral sclerosis
EP16713833.8A EP3273957B1 (en) 2015-03-26 2016-03-25 Biotin for treating demyelinating neuropathies
PCT/EP2016/056696 WO2016151132A1 (en) 2015-03-26 2016-03-25 Biotin for treating amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
ME03567B true ME03567B (me) 2020-07-20

Family

ID=52779582

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-285A ME03567B (me) 2015-03-26 2016-03-25 Biotin za lečenje demijelinizacionih neuropatija

Country Status (23)

Country Link
US (2) US10357480B2 (me)
EP (2) EP3072513A1 (me)
JP (1) JP6752874B2 (me)
KR (1) KR20170131543A (me)
CN (2) CN111973592A (me)
AU (1) AU2016238759B2 (me)
BR (1) BR112017020408A2 (me)
CA (1) CA2980660A1 (me)
CY (1) CY1122374T1 (me)
DK (1) DK3273957T3 (me)
EA (1) EA034394B1 (me)
ES (1) ES2748354T3 (me)
HR (1) HRP20191491T1 (me)
HU (1) HUE046116T2 (me)
IL (1) IL254619B (me)
LT (1) LT3273957T (me)
MA (1) MA41809B1 (me)
ME (1) ME03567B (me)
PL (1) PL3273957T3 (me)
PT (1) PT3273957T (me)
RS (1) RS59149B1 (me)
SI (1) SI3273957T1 (me)
WO (1) WO2016151132A1 (me)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
CN112386703A (zh) * 2020-01-15 2021-02-23 李启芳 治疗als的联合用药物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885976A (en) * 1995-05-08 1999-03-23 Sandyk; Reuven Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions
DK1575531T3 (da) 2002-09-27 2011-11-21 Biogen Idec Inc Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta
US20050249823A1 (en) * 2003-11-04 2005-11-10 Murphy Tanya K Methods for the prevention or amelioration of neuropsychiatric and related diseases
US7105183B2 (en) * 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
AU2012245205B2 (en) * 2011-04-21 2017-06-01 The Regents Of The University Of California, A California Corporation Compositions and methods for the treatment of neuromyelitis optica
EP2731611B1 (en) * 2011-07-13 2019-09-18 Cytokinetics, Inc. Combination therapie for als
US9789092B2 (en) 2013-04-29 2017-10-17 Assistance Publique—Hopitaux de Paris Biotin for use in treating X-linked adrenoleukodystrophy
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
IL254619B (en) 2020-03-31
CY1122374T1 (el) 2021-01-27
RS59149B1 (sr) 2019-09-30
EP3072513A1 (en) 2016-09-28
JP2018512451A (ja) 2018-05-17
AU2016238759B2 (en) 2020-08-06
HUE046116T2 (hu) 2020-02-28
IL254619A0 (en) 2017-11-30
DK3273957T3 (da) 2019-11-11
EA201792124A1 (ru) 2018-04-30
KR20170131543A (ko) 2017-11-29
EP3273957B1 (en) 2019-08-14
WO2016151132A1 (en) 2016-09-29
NZ735528A (en) 2021-09-24
CN111973592A (zh) 2020-11-24
US10357480B2 (en) 2019-07-23
PT3273957T (pt) 2019-09-18
US20180125825A1 (en) 2018-05-10
AU2016238759A1 (en) 2017-10-05
LT3273957T (lt) 2019-11-11
ES2748354T3 (es) 2020-03-16
EP3273957A1 (en) 2018-01-31
CA2980660A1 (en) 2016-09-29
JP6752874B2 (ja) 2020-09-09
MA41809A (fr) 2018-01-30
BR112017020408A2 (pt) 2018-06-05
CN107405335A (zh) 2017-11-28
US20190314342A1 (en) 2019-10-17
MA41809B1 (fr) 2019-12-31
PL3273957T3 (pl) 2020-01-31
HRP20191491T1 (hr) 2019-11-15
SI3273957T1 (sl) 2019-11-29
EA034394B1 (ru) 2020-02-04

Similar Documents

Publication Publication Date Title
IL244096A0 (en) Reinforcement for moving an object
GB201500989D0 (en) Process
IL278247B (en) mct4 inhibitors to treat the disease
HK1244217A1 (zh) 用於治療蛋白質病的方法
IL256116A (en) geometric
HK1258823A1 (zh) 用於治療肌營養不良的方法
HK1253238A1 (zh) 用於治療疾病的gls1抑制劑
GB201502893D0 (en) Process
GB201502894D0 (en) Process
GB201501952D0 (en) Process
HK1255871A1 (zh) 用於治療骨髓瘤的賽度替尼
GB201522243D0 (en) Treatment
GB201502137D0 (en) Treatment
HK1250649A1 (zh) 用於治療白血病的抗-s100a8
HK1255481A1 (zh) 用於治療hcv的方法
GB201505311D0 (en) Process
GB201503635D0 (en) Process
GB201501953D0 (en) Process
GB201500990D0 (en) Process
GB201504948D0 (en) Process
GB201502814D0 (en) Process
GB201508841D0 (en) Treatment
HUE046116T2 (hu) Biotin, demielinizációs neuropátiák kezelésére
GB201501423D0 (en) Process
GB201503607D0 (en) Process